Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.
Kumada H, et al. Among authors: suzuki f.
J Gastroenterol. 2018 May;53(5):689. doi: 10.1007/s00535-017-1409-z.
J Gastroenterol. 2018.
PMID: 29134328
Free PMC article.